Navigation Links
Gilead to Topple GSK as the Top Player in the Anti-Infectives Drug Market in 2014
Date:11/12/2008

Stringent, Yet Ill-Defined, Approval Standards Make it Difficult for Companies to Bring Hospital Antibiotics to Market, According to a New Report from Decision Resources

WALTHAM, Mass., Nov. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Gilead will topple GlaxoSmithKline (GSK) as the top player in the anti-infectives drug market in 2014. According to the new report entitled Commercial Outlook for Anti-Infectives: 2003-2014, GSK's fall will be due to generic erosion and a sparse anti-infectives pipeline. Gilead's rise will be due to its remarkable growth in HIV driven by its blockbuster products, Truvada and Atripla.

The report also finds that increasingly stringent, yet ill-defined, approval standards make it difficult for companies to bring hospital antibiotics to market. The FDA's heightened scrutiny of hospital antibiotics has resulted in extended review periods, cancelled advisory meetings, postponed PDUFA dates and the issuance of multiple consecutive approvable letters requesting further data.

"We believe there is discordance between the FDA's expectations and the submission data presented by drug developers," said Sylvia Eash, Ph.D., analyst at Decision Resources. "As a result, the lack of FDA guidance that clearly defines these standards has emerged as the greatest challenge for drug developers who are left to wonder how the approval process will change while their late-stage hospital antibiotic candidates await further regulatory decisions. Agents suffering from these regulatory uncertainties include J&J's Doribax, Pfizer's Zeven, Theravance's telavancin and J&J's ceftobiprole."

The report is the first of its kind from Decision Resources, outlining the entire drug market for anti-bacterials, anti-virals and anti-fungals. Each drug class is thoroughly dissected with robust data on major brands, supporting brands, late stage and early stage R&D candidates. The 251 page report also includes the therapy area rankings by company from 2003-2014, the sales by class from 2003-2014 and key events within the anti-infectives market.

In addition to the report, Commercial Outlook for Anti-Infectives: 2003-2014 will include an interactive forecast model for anti-infectives as well as a unique slide deck featuring analysis on the anti-infective franchises of the top 20 pharma companies.

About Commercial Outlook for Anti-Infectives: 2003-2014

Commercial Outlook for Anti-Infectives: 2003-2014 is part of the Pharmaview franchise from Decision Resources. Offering top-down sales numbers, complete overviews of all major drugs on the market and in late and early-stage development, this report is a must-have for any biopharmaceutical company in, or looking to break into, the anti-infectives market or any company partnering with or selling into a drug company currently in the anti-infectives market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
2. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
3. Backe Digital-Brand-Marketing Blends Traditional Advertising with Expanded Digital Services
4. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
5. Spherix Transfers Stock Listing to Nasdaq Capital Market
6. MichBio Expo Will Feature Sessions for Michigan Manufacturers Interested in Entering Medical Device Market
7. Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts
8. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
9. WellSpring Pharmaceutical Corp. Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands
10. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
11. Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):